PDI, a provider of commercialization services to the biopharmaceutical industry, has extended its sales services agreement with a top-10 pharmaceutical company through April 2009 to promote its leading anti-viral medication on a seasonal basis.
Subscribe to our email newsletter
The company will continue to utilize PDI’s Select Access team for an additional two seasons to reach primary care physicians and will be exclusive to pediatric targets. This initiative is expected to generate approximately $10.5 million during the 2007-2008 promotional seasonal.
Nancy Connelly, senior vice president of sales services at PDI, said: “Select Access has continually proven to be an impactful and highly flexible asset that helps our clients maximize their return on investment.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.